肝炎治療薬の世界市場レポート 2025年

肝炎治療薬の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.2％で247億6,000万米ドルに成長します。予測期間の成長は、新規の直接作用型抗ウイルス薬の導入、肝炎感染の有病率の増加、肝炎の予防と治療に対する政府のイニシアチブの高まり、肝炎に対する個別化医療アプローチの進歩、発展途上国における肝炎治療薬へのアクセス拡大などに起因すると考えられます。予測期間における主な動向としては、インターフェロンベース治療からインターフェロンフリー治療への移行、C型肝炎に対する汎遺伝子型抗ウイルス薬の開発、肝線維化評価のための非侵襲的診断法の統合、B型肝炎に対する併用療法の探求、公衆衛生の脅威としてのウイルス性肝炎の撲滅への関心の高まりなどが挙げられます。

様々なタイプの肝炎患者の増加が肝炎治療薬市場の成長を大きく促進しています。様々なタイプの肝炎が異なる治療薬を必要とするため、肝炎治療薬の需要が増加しています。例えば、スイスに本部を置く国際公衆衛生機関である世界保健機関（WHO）によると、2022年6月には2億9,600万人が慢性B型肝炎に感染しており、毎年平均150万人が新たに感染しています。このような肝炎感染者の増加は、肝炎治療薬の必要性と消費量を増加させます。このように、異なるタイプの肝炎の増加は、予測期間における肝炎治療薬の成長を促進すると予想されます。

研究開発への投資の増加は、今後数年間の肝炎治療薬市場の成長を促進すると予想されます。研究開発とは、新しい製品、プロセス、サービスを発見、実験、発明、開発するため、または既存のものを強化するために、企業、機関、組織によって実施される研究業務を指します。研究開発への投資は、財務的成長、社会的改善、企業の成功、持続可能性に大きく貢献し、いくつかの分野における進歩や創造性を促進します。例えば、2023年5月、オーストラリア政府の最高立法府であるオーストラリア議会によると、政府は2022～2023年に研究開発に121億米ドルを投資する予定です。これは前年比3.2％増です。したがって、研究開発への投資増が肝炎治療薬市場を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の肝炎治療薬市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の肝炎治療薬市場の成長率分析
• 世界の肝炎治療薬市場の実績：規模と成長、2019～2024年
• 世界の肝炎治療薬市場の予測：規模と成長、2024～2029年、2034年
• 世界の肝炎治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の肝炎治療薬市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• インターフェロンアルファ
• HIV NRTI
• ヌクレオチドポリメラーゼまたはNS5A阻害剤の組み合わせ
• C型肝炎プロテアーゼまたはNS5A阻害剤の組み合わせ
• NS5A阻害剤
• ヌクレオチドポリメラーゼ阻害剤
• ヌクレオシドアナログ抗ウイルス薬
• 血栓形成促進剤
• 世界の肝炎治療薬市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 注射
• 世界の肝炎治療薬市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の肝炎治療薬市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• A型肝炎
• B型肝炎
• C型肝炎
• D型肝炎
• E型肝炎
• 世界の肝炎治療薬市場：インターフェロンアルファのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ペグインターフェロンアルファ
• 非ペグ化インターフェロンアルファ
• 世界の肝炎治療薬市場：HIV NRTIのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ジドブジン
• ラミブジン
• アバカビル
• テノホビル
• 世界の肝炎治療薬市場：ヌクレオチドポリメラーゼまたはNS5A阻害剤の組み合わせのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ソホスブビルまたはベルパタスビル
• ソホスブビルまたはレディパスビル
• 世界の肝炎治療薬市場：C型肝炎プロテアーゼまたはNS5A阻害剤の組み合わせのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• グレカプレビルまたはピブレンタスビル
• パリタプレビルまたはオムビタスビルまたはダサブビル
• 世界の肝炎治療薬市場：NS5A阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ダクラタスビル
• レディパスビル
• ベルパタスビル
• 世界の肝炎治療薬市場：ヌクレオチドポリメラーゼ阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ソホスブビル
• ダサブビル
• 世界の肝炎治療薬市場：ヌクレオシドアナログ抗ウイルス薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アデホビル
• エンテカビル
• ラミブジン
• 世界の肝炎治療薬市場：血栓形成促進剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• エルトロンボパグ
• ロミプロスチム

第7章 地域別・国別分析

• 世界の肝炎治療薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の肝炎治療薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 肝炎治療薬市場：競合情勢
• 肝炎治療薬市場：企業プロファイル
  • Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abbott Laboratories
• AbbVie Inc.
• Arbutus Biopharma Corporation
• Aspen Pharmacare Holdings Limited
• Aurobindo Pharma Limited
• Beximco Pharmaceuticals Ltd.
• Biocon Limited
• Bristol-Myers Squibb Company
• Cadila Healthcare Limited
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Enanta Pharmaceuticals Inc.
• Hetero Drugs Limited
• Laurus Labs Limited
• Lupin Pharmaceuticals Inc.

第32章 世界市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 市場の最近の動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 肝炎治療薬市場2029年-最も新しい機会を提供する国
• 肝炎治療薬市場2029年-最も新しい機会を提供するセグメント
• 肝炎治療薬市場2029年-成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Hepatitis drugs refer to medications that aggravate liver inflammation. A number of viruses (viral hepatitis), substances, medications, alcohol, certain genetic abnormalities, an overactive immune system that mistakenly assaults the liver (autoimmune hepatitis), and other factors can result in liver inflammation.

The main type of hepatitis drugs interferon alphas, HIV NRTIS, nucleotide polymerase / NS5A inhibitor combinations, hepatitis C protease / NS5A inhibitor combinations, NS5A inhibitors, nucleotide polymerase inhibitors, nucleoside analog antivirals, and thrombopoiesis stimulating agents. The interferon alphas are the innate immune system in response to environmental exposures such as viral infections. Interferon alpha has been developed in different formulations for the treatment but mainly for chronic hepatitis C. The drugs are consumed through oral or injection route of administration and are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies. These drugs are used to treat hepatitis A, hepatitis B, hepatitis C, hepatitis D and hepatitis E.

The hepatitis drugs market research report is one of a series of new reports from The Business Research Company that provides hepatitis drugs market statistics, including hepatitis drugs industry global market size, regional shares, competitors with a hepatitis drugs market share, detailed hepatitis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis drugs industry. This hepatitis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatitis drugs market size has grown steadily in recent years. It will grow from $20.04 billion in 2024 to $20.98 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to discovery of antiviral drugs targeting hepatitis viruses, advances in diagnostic technologies for hepatitis, growing awareness of The global burden of hepatitis, expansion of hepatitis vaccination programs, development of interferon-basedTherapies for hepatitis.

The hepatitis drugs market size is expected to see steady growth in the next few years. It will grow to $24.76 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to introduction of novel direct-acting antiviral drugs, increasing prevalence of hepatitis infections, rise in government initiatives for hepatitis prevention and treatment, advances in personalized medicine approaches for hepatitis, expansion of access to hepatitis drugs in developing countries. Major trends in the forecast period include transition from interferon-based to interferon-free therapies, development of pan-genotypic antiviral drugs for hepatitis c, integration of non-invasive diagnostic methods for liver fibrosis assessment, exploration of combination therapies for hepatitis b, growing focus on the elimination of viral hepatitis as a public health threat.

The increase in number of cases of different types of hepatitis is significantly driving the growth of the hepatitis drug market. Various types of hepatitis need different drugs for treatment, which increases the demand for hepatitis drugs. For instance, in June 2022, according to the World Health Organization (WHO), a Switzerland based international public health organization, 296 million people had a chronic hepatitis B infection, with an average of 1. 5 million new infections every year. This increasing number of hepatitis infections will invariably increase the need for and consumption of hepatitis drugs. Thus, the increasing number of different types of hepatitis is expected to propel the growth of hepatitis drugs in the forecast period.

The rising investment in research and development is expected to propel the growth of the hepatitis drug market in the coming years. Research and development refer to the research operations carried out by businesses, institutions, or organizations to discover, experiment, invent, and develop new goods, processes, or services, or to enhance current ones. Investments in research and development contribute considerably to financial growth, societal improvement, corporate success, and sustainability, promoting advancement and creativity in several areas. For instance, in May 2023, according to the Parliament of Australia, an Australia-based government supreme legislative branch, the government is going to invest $12. 1 billion in research and development in 2022-23. This is a 3. 2% increase over the previous year. Therefore, the rising investment in research and development is driving the hepatitis drugs market.

Leading companies in the hepatitis drugs market are concentrating on developing innovative formulations to enhance treatment efficacy, improve patient compliance, minimize side effects, and address the various strains of the hepatitis virus. The FDA Fast Track designation is a process aimed at accelerating the development and review of drugs that treat serious conditions and fulfill an unmet medical need. Medications granted this designation are intended to help patients access new therapies more swiftly, particularly for serious or life-threatening diseases. For example, in February 2024, GSK plc, a UK-based pharmaceutical company, received the U.S. Food and Drug Administration (FDA) Fast Track designation for its drug bepirovirsen, aimed at treating chronic hepatitis B (CHB). This designation is significant as it seeks to expedite the development and review process for therapies addressing unmet medical needs in serious conditions.

Major companies operating in the hepatitis drug market are focusing on innovative products, such as Vemlidy (tenofovir alafenamide), to better meet the needs of their existing consumers. Vemlidy (Tenofovir alafenamide) is an antiretroviral medicine belonging to the nucleotide reverse transcriptase inhibitor (NRTI) class used to treat HIV (Human Immunodeficiency Virus) and persistent hepatitis B virus infections. For instance, in November 2022, Gilead Sciences Inc., a US-based biopharmaceutical company, announced the approval of Vemlidy (tenofovir alafenamide) at a dose of 25 mg for the treatment of chronic hepatitis B virus infection in pediatric individuals. Vemlidy is a new, targeted tenofovir prodrug used as a once-daily therapy for individuals with persistent HBV infection with compensatory liver disease. It is indicated as a recommended or first-line therapy for individuals with chronic HBV and aggravated liver disease in AASLD and EASL recommendations.

In November 2022, Merck & Co., a US-based healthcare company, acquired Imago BioSciences for an undisclosed amount. This acquisition is aimed at enhancing Merck's oncology portfolio by integrating Imago BioSciences' innovative treatments for blood disorders, particularly the LSD1 inhibitor bomedemstat, which shows potential in treating various hematological malignancies. This move is expected to strengthen Merck's capabilities in addressing unmet medical needs. Imago BioSciences is a US-based clinical-stage biotechnology company focused on developing therapies for hematologic diseases.

Major companies operating in the hepatitis drugs market include Gilead Sciences Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Abbott Laboratories, AbbVie Inc., Arbutus Biopharma Corporation, Aspen Pharmacare Holdings Limited, Aurobindo Pharma Limited, Beximco Pharmaceuticals Ltd., Biocon Limited, Bristol-Myers Squibb Company, Cadila Healthcare Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Enanta Pharmaceuticals Inc., Hetero Drugs Limited, Laurus Labs Limited, Lupin Pharmaceuticals Inc., Micro Labs Limited, Mylan N. V., Natco Pharma Limited, Novartis International AG, Roche Holding AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited, Vir Biotechnology Inc., Genentech Inc., Eisai Pharmaceuticals India Pvt. Ltd.

North America was the largest region in the hepatitis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hepatitis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The hepatitis drugs market consists of sales of ribavirin, elbasvir-grazoprevir, and glecaprevir-pibrentasvir. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatitis Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatitis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatitis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hepatitis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Interferon Alphas; HIV NRTIs; Nucleotide Polymerase Or NS5A Inhibitor Combinations; Hepatitis C Protease Or NS5A Inhibitor Combinations; NS5A Inhibitors; Nucleotide Polymerase Inhibitors; Nucleoside Analogue Antivirals; Thrombopoiesis Stimulating Agents
• 2) By Route Of Administration: Oral; Injection
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D; Hepatitis E
• Subsegments:
• 1) By Interferon Alphas: Pegylated Interferon Alpha; Non-Pegylated Interferon Alpha
• 2) By HIV NRTIs: Zidovudine; Lamivudine; Abacavir; Tenofovir
• 3) By Nucleotide Polymerase Or NS5A Inhibitor Combinations: Sofosbuvir Or velpatasvir; Sofosbuvir Or ledipasvir
• 4) By Hepatitis C Protease Or NS5A Inhibitor Combinations: Glecaprevir Or pibrentasvir; Paritaprevir Or ombitasvir Or dasabuvir
• 5) By NS5A Inhibitors: Daclatasvir; Ledipasvir; Velpatasvir
• 6) By Nucleotide Polymerase Inhibitors: Sofosbuvir; Dasabuvir
• 7) By Nucleoside Analogue Antivirals: Adefovir; Entecavir; Lamivudine
• 8) By Thrombopoiesis Stimulating Agents: Eltrombopag; Romiplostim
• Companies Mentioned: Gilead Sciences Inc.; F. Hoffmann-La Roche Ltd; GlaxoSmithKline plc; Johnson & Johnson; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hepatitis Drugs Market Characteristics

3. Hepatitis Drugs Market Trends And Strategies

4. Hepatitis Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hepatitis Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hepatitis Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hepatitis Drugs Market Growth Rate Analysis
• 5.4. Global Hepatitis Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hepatitis Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hepatitis Drugs Total Addressable Market (TAM)

6. Hepatitis Drugs Market Segmentation

• 6.1. Global Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interferon Alphas
• HIV NRTIs
• Nucleotide Polymerase Or NS5A Inhibitor Combinations
• Hepatitis C Protease Or NS5A Inhibitor Combinations
• NS5A Inhibitors
• Nucleotide Polymerase Inhibitors
• Nucleoside Analogue Antivirals
• Thrombopoiesis Stimulating Agents
• 6.2. Global Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injection
• 6.3. Global Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis A
• Hepatitis B
• Hepatitis C
• Hepatitis D
• Hepatitis E
• 6.5. Global Hepatitis Drugs Market, Sub-Segmentation Of Interferon Alphas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pegylated Interferon Alpha
• Non-Pegylated Interferon Alpha
• 6.6. Global Hepatitis Drugs Market, Sub-Segmentation Of HIV NRTIs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Zidovudine
• Lamivudine
• Abacavir
• Tenofovir
• 6.7. Global Hepatitis Drugs Market, Sub-Segmentation Of Nucleotide Polymerase Or NS5A Inhibitor Combinations, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sofosbuvir Or velpatasvir
• Sofosbuvir Or ledipasvir
• 6.8. Global Hepatitis Drugs Market, Sub-Segmentation Of Hepatitis C Protease Or NS5A Inhibitor Combinations, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glecaprevir Or pibrentasvir
• Paritaprevir Or ombitasvir Or dasabuvir
• 6.9. Global Hepatitis Drugs Market, Sub-Segmentation Of NS5A Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Daclatasvir
• Ledipasvir
• Velpatasvir
• 6.10. Global Hepatitis Drugs Market, Sub-Segmentation Of Nucleotide Polymerase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sofosbuvir
• Dasabuvir
• 6.11. Global Hepatitis Drugs Market, Sub-Segmentation Of Nucleoside Analogue Antivirals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adefovir
• Entecavir
• Lamivudine
• 6.12. Global Hepatitis Drugs Market, Sub-Segmentation Of Thrombopoiesis Stimulating Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Eltrombopag
• Romiplostim

7. Hepatitis Drugs Market Regional And Country Analysis

• 7.1. Global Hepatitis Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hepatitis Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hepatitis Drugs Market

• 8.1. Asia-Pacific Hepatitis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hepatitis Drugs Market

• 9.1. China Hepatitis Drugs Market Overview
• 9.2. China Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hepatitis Drugs Market

• 10.1. India Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hepatitis Drugs Market

• 11.1. Japan Hepatitis Drugs Market Overview
• 11.2. Japan Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hepatitis Drugs Market

• 12.1. Australia Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hepatitis Drugs Market

• 13.1. Indonesia Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hepatitis Drugs Market

• 14.1. South Korea Hepatitis Drugs Market Overview
• 14.2. South Korea Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hepatitis Drugs Market

• 15.1. Western Europe Hepatitis Drugs Market Overview
• 15.2. Western Europe Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hepatitis Drugs Market

• 16.1. UK Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hepatitis Drugs Market

• 17.1. Germany Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hepatitis Drugs Market

• 18.1. France Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hepatitis Drugs Market

• 19.1. Italy Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hepatitis Drugs Market

• 20.1. Spain Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hepatitis Drugs Market

• 21.1. Eastern Europe Hepatitis Drugs Market Overview
• 21.2. Eastern Europe Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hepatitis Drugs Market

• 22.1. Russia Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hepatitis Drugs Market

• 23.1. North America Hepatitis Drugs Market Overview
• 23.2. North America Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hepatitis Drugs Market

• 24.1. USA Hepatitis Drugs Market Overview
• 24.2. USA Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hepatitis Drugs Market

• 25.1. Canada Hepatitis Drugs Market Overview
• 25.2. Canada Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hepatitis Drugs Market

• 26.1. South America Hepatitis Drugs Market Overview
• 26.2. South America Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hepatitis Drugs Market

• 27.1. Brazil Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hepatitis Drugs Market

• 28.1. Middle East Hepatitis Drugs Market Overview
• 28.2. Middle East Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hepatitis Drugs Market

• 29.1. Africa Hepatitis Drugs Market Overview
• 29.2. Africa Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hepatitis Drugs Market Competitive Landscape And Company Profiles

• 30.1. Hepatitis Drugs Market Competitive Landscape
• 30.2. Hepatitis Drugs Market Company Profiles
  • 30.2.1. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hepatitis Drugs Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. AbbVie Inc.
• 31.3. Arbutus Biopharma Corporation
• 31.4. Aspen Pharmacare Holdings Limited
• 31.5. Aurobindo Pharma Limited
• 31.6. Beximco Pharmaceuticals Ltd.
• 31.7. Biocon Limited
• 31.8. Bristol-Myers Squibb Company
• 31.9. Cadila Healthcare Limited
• 31.10. Cipla Limited
• 31.11. Dr. Reddy's Laboratories Ltd.
• 31.12. Enanta Pharmaceuticals Inc.
• 31.13. Hetero Drugs Limited
• 31.14. Laurus Labs Limited
• 31.15. Lupin Pharmaceuticals Inc.

32. Global Hepatitis Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hepatitis Drugs Market

34. Recent Developments In The Hepatitis Drugs Market

35. Hepatitis Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Hepatitis Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hepatitis Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hepatitis Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer